Dupilumab Provides Significant Clinical Benefit in a Phase 3 Trial in Adolescents with Uncontrolled Atopic Dermatitis Irrespective of Prior Systemic Immunosuppressant Use

Acta Derm Venereol. 2021 Jul 15;101(7):adv00504. doi: 10.2340/00015555-3848.
No abstract available

Publication types

  • Clinical Trial, Phase III

MeSH terms

  • Adolescent
  • Antibodies, Monoclonal, Humanized
  • Dermatitis, Atopic* / diagnosis
  • Dermatitis, Atopic* / drug therapy
  • Double-Blind Method
  • Eczema*
  • Humans
  • Immunosuppressive Agents / adverse effects
  • Severity of Illness Index
  • Treatment Outcome

Substances

  • Antibodies, Monoclonal, Humanized
  • Immunosuppressive Agents
  • dupilumab